Correlation between soluble receptor for advanced glycation end products levels and coronary artery disease in postmenopausal nondiabetic women

Table 1 Baseline characteristics of the study subjects

Variable	Group I (n = 55)	Group II (n = 55)	P value
Age (yr)	57.58 ± 7.75	56.29 ± 7.69	0.38
BMI (kg/m²)	25.41 ± 3.05	24.81 ± 3.79	0.35
WC (cm)	83.02 ± 5.17	81.42 ± 6.11	0.14
Serum CHOL (mg/dL)	175.33 ± 40.68	180.12 ± 37.12	0.52
Serum TG (mg/dL)	175.16 ± 48.67	150.09 ± 42.67	0.05
Serum HDL-C (mg/dL)	38.57 ± 6.89	40.59 ± 8.17	0.16
Serum LDL-C (mg/dL)	123.68 ± 27.73	113.17 ± 31.58	0.06
FBS (mg/dL)	92.89 ± 8.81	95.71 ± 10.14	0.12
PPBS (mg/dL)	133.33 ± 5.53	133.15 ± 3.76	0.84
HbA1c (%)	5.24 ± 0.19	5.28 ± 0.14	0.14
Serum creatinine (mg/dL)	0.79 ± 0.16	0.85 ± 0.23	0.09
Serum hsCRP (μg/mL)	5.26 ± 1.94	1.41 ± 0.44	0.00b
Plasma HC (μmol/L)	18.13 ± 5.39	12.83 ± 3.99	0.00b
Lp(a) (μg/mL)	294.36 ± 202.22	251.22 ± 221.42	0.28
sRAGE (pg/mL)	285 (30-2490)	540 (90-3450)	0.02a
Category 1 (< 225)	24	4	0.00b
Category 2 (≥ 225-< 397.5)	8	19	0.01a
Category 3 (≥ 397.5-< 730)	13	15	0.66
Category 4 (≥ 730)	10	17	0.12
Hypertension	30	24	0.25
Family history	26	14	0.01a

^aP < 0.05.

^bP < 0.01.

Data are means ± SD, median (interquartile range), or frequency counts, as appropriate. BMI: Body Mass Index; CHOL: Cholesterol; FBS: Fasting blood sugar; HbA1c: Glycosylated hemoglobin; HC: Homocysteine; HDL-C: High-density lipoprotein cholesterol; hsCRP: High-sensitivity C-reactive protein; LDL-C: Low-density lipoprotein cholesterol; Lp(a): Lipoprotein (a); PPBS: Post prandial blood sugar; sRAGE: Soluble receptor for advanced glycation end products; TG: Triglycerides; WC: Waist circumference.